| 前收市價 | 3.1600 |
| 開市 | 3.1400 |
| 買盤 | 0.0000 x 0 |
| 賣出價 | 0.0000 x 0 |
| 今日波幅 | 3.0601 - 3.1900 |
| 52 週波幅 | 2.4300 - 5.0500 |
| 成交量 | |
| 平均成交量 | 41,164 |
| 市值 | 170.051M |
| Beta 值 (5 年，每月) | 0.96 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.6000 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
Insider MonkeyInventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript March 28, 2024 Inventiva S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the Inventiva Annual Results 2023 conference call. At this […]
BenzingaInventiva's Lanifibranor Significantly Reduces NAFLD and Improves Type 2 Diabetes Control, Phase 2 Study Shows
Inventiva SA (NASDAQ: IVA) announced the topline results of Phase 2 clinical study evaluating lanifibranor in patients with NAFLD and type 2 diabetes mellitus. The study achieved the primary efficacy endpoint with a 44% reduction of Intra Hepatic Triglycerides (fat in the bloodstream) compared to 12% in the placebo arm. This result is consistent with the Phase 2b NATIVE trial findings, in which lanifibranor demonstrated a statistically significant effect on steatosis reduction as measured by CAP
